Takara Bio : Financial Results Presentation (November 11, 2021)

Financial Results Presentation

for the second Quarter

Ended September 30, 2021

November 11, 2021

This is an English translation from Japanese presentation material.

Contents

• Consolidated Quarterly Financial Results for FY2022 (for the Second Quarter Ended Sep. 30, 2021)
• Consolidated Financial Forecast for FY2022
• Business Progress and Future Measures

2

1

Consolidated Quarterly Financial Results for FY2022

(for the Second Quarter Ended Sep. 30, 2021)

								Reagents
				FY2022	Y/Y	Comparison
				with Aug.3	Growth in the new Coronavirus PCR test-
	(million yen)	2	nd	-quarter
			forecast	related product. Reagents for general
	Net Sales			31,551	+14,158	+1,851	research are recovering
			+81.4%	+6.2%	Instruments
						Strong sales of PCR instrument.
						+12,629	+1,908
		Reagents			25,966	CDMO
				+94.7%	+7.9%
						Increased in revenue for Regenerative
		Instruments			712	+245	▲78	Medicine, Gene Analysis and Testing,
				+52.6%	▲9.9%	and Vaccine on CDMO
						Gene therapy
						+1,358	+5
		CDMO			4,732	Decrease in sales of investigational
				+40.3%	+0.1%
						products
		Gene			140	▲75	+16	Gross profit
				Increased due to higher sales and
		therapy			▲35.0%	+13.4%
					improvement in the profitability of CDMO
	Gross profit			23,495	+11,667	+2,544	Operating profit
						+98.6%	+12.1%	Despite an increase in general and
	Operating				+10,368	+2,705	administrative expenses, the increase in
			14,105	gross profit was significant, resulting in
		profit			+277.5%	+23.7%	an increase in profits.

3 (NOTE) Explanation of year-on-year changes

2nd Quarter Ended Sep. 30, 2021:
	Sales for Reagents
Sales Breakdown		Sales Breakdown by Region
(100 million yen)
300			21/03期
New Coronavirus		133
PCR test-related	259	FY2021
General research		⽇本			+67
			Japan
200		120	⽶国			+8
	U.S.
			中国				+22
	133		China
118		欧州					+21
	40		Europe
100		韓国				+4	+0
		139	Korea
		インド				+0 +4
	93		India
			22/03期			259
0			FY2022
20/03FY2020期	21/FY20213期	22/FY20223期	100	150	200	250
						(100 million yen)
4

2

2nd Quarter Ended Sep. 30, 2021;

Operating Profit

Y/Y Change

Comparison with Aug. 3 forecast

Aug. 3

21/ 3期

37

8/3予想

114

FY20

FY2021

forecast

売上差

売上差

+13

Sales

Sales

+91

profit

Sales

上

売

構成差

+20

構成差

+12

Gross

総Composition

Composition

益

利

為替差

+5

為替差

▲0

Exchange

Exchange

R&D

▲2

R&D

+0

研究開発費

研究開発費

expenses

expenses

Personnel

Personnel

⼈件費※

▲6

⼈件費※

+0

Expense*

Expense*

Other

▲4

Other

その他経費

その他経費

+1

expenses

expenses

(億

(億

22/03期

22/03期

141

円)

FY20FY2022

141

円

)

FY2022

20

80

140

100

120

140

(100 million yen)

(100 million yen)

• * Excluding R&D personnel expenses

Contents

• Consolidated Quarterly Financial Results for FY2022 (for the Second Quarter Ended Sep. 30, 2021)
• Consolidated Financial Forecast for FY2022
• Business Progress and Future Measures

6

3

Consolidated Financial Forecast for FY2022

(for the Year Ending March 31, 2022)

				FY2022	Y/Y	Comparison
				with Aug. 3
			(millions yen)	Full-year
				forecast
			Net sales	59,300	+13,213	+5,100
			+28.7%	+9.4%
			Reagents	46,375	+11,186	+5,781
			+31.8%	+14.2%
			Instruments	1,388	▲337	▲153
			▲19.6%	▲9.9%
			CDMO	11,388	+2,486	+41
			+27.9%	+0.4%
			Gene therapy	146	▲121	▲569
			▲45.4%	▲79.5%
		Gross profit	40,502	+8,630	+3,235
		+27.1%	+8.7%
			Operating	20,000	+6,047	+3,000
			profit	+43.3	+17.6%

Reagents

Reagents for general research are recovering in earnest. Growth in the new Coronavirus PCR test-related product.

Instruments

Sales declined as demand for PCR instrument related to the new Coronavirus PCR test subsided.

CDMO

Increased in revenue for Regenerative Medicine, Gene Analysis and Testing, and Vaccine on CDMO

Gene therapy

Decrease in sales of investigational products

Gross profit

Increased due to higher sales and improvement in the profitability of CDMO

Operating profit

Forecast 13 consecutive years of profit growth.

7 (NOTE) Explanation of year-on-year changes

Full-year Forecast for FY2022:

Sales for Reagents (1)

Sales Breakdown

Sales Breakdown by Region

(100 million yen)

New Coronavirus

463

21/03期

PCR test-related

FY2021

351

400

General research

⽇本

+48

351

180

Japan

⽶国

300

U.S.

+18

130

中国

+27

248

China

Europe

+15

200

欧州

283

Korea

+1

韓国

100

221

India

+3

インド

FY2022

22/03期

463

0

Forecast

予想

FY2020

FY2021

FY2022

40,000

50,000

30,000

20/03期

21/03期

22/03期

300

400

(100 million yen)

Forecast

予想

8

4

Full-year Forecast for FY2022: Sales for Reagents (2), by Region

			Japan								China
(100 million yen)
		2nd half		160				2nd half
15,000150		1st half							1st half
			112		56		(100 million yen)
100						100						98
10,0			76				10,	59		71	301	48
	61						180 44
5,00050	35			104		5,00050		171
							32
			36								27		50
	26					27
0							0
	FY2020	FY2021		FY2022		FY2020	FY2021	FY2022
		20/03期	21/ 3期		22/ 3期			20/03期	21/ 3期	22/ 3期
					予想							予想
				Forecast							Forecast

9

Full-year Forecast for FY2022: Sales for Reagent (3), by Region

				U.S.								Europe
(100 million yen)
			2nd half		108				2nd half
	10,100		1st half	90				10,000		1st half
		88				(100 million
						yen)
						56									76
		44	47								61
	50							50							36
	5,000							5,000	27			43
		44	43	52
					14					40
											18
	0							0	13
		FY2020	FY2021	FY2022		FY2020		FY2021	FY2022
			20/03期	21/03期		22/03期			20/03期		21/03期	22/03期
					Forecast								Forecast
						予想								予想

10

5